Sponsors (4)
Rescheduling marijuana to Schedule III would expand medical access, research, and commercial opportunities but would also create insurance, regulatory, and enforcement transitions that produce short-term uncertainty for patients, businesses, and officials.
Patients with chronic conditions and people with disabilities would gain easier access to marijuana-based medicines because moving marijuana to Schedule III enables medical prescribing and reduces the Schedule I prohibition.
Scientists and medical researchers would face fewer federal barriers to study marijuana, enabling more clinical research and stronger evidence on therapeutic uses and risks.
Small businesses, pharmaceutical firms, and taxpayers could see commercial growth, new prescription products, job creation, and additional tax revenue as Schedule III status permits expanded legal markets.
State-legal cannabis businesses, banks, and consumers could face regulatory, banking, and tax uncertainty as rescheduling interacts with existing state markets and federal financial rules.
Patients with chronic conditions may encounter new prescribing restrictions or insurance coverage limits because Schedule III status can change prescribing rules and insurer policies.
Law enforcement, prosecutors, and courts would need to adjust charging and enforcement practices, creating transitional confusion and uneven application across jurisdictions.
Based on analysis of 2 sections of legislative text.
Directs the Attorney General to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act within 60 days, bypassing normal scheduling procedures.
Introduced August 12, 2025 by W. Greg Steube · Last progress August 12, 2025
Requires the Attorney General to reclassify "marijuana" (defined by the Controlled Substances Act) from Schedule I to Schedule III by administrative order within 60 days of enactment, overriding the usual multi-step scheduling procedures in the CSA. The change would move marijuana to a lower federal control level but would not itself legalize marijuana under federal law or automatically approve any product for medical use. The directive is narrow in form (one substantive mandate plus a short title) but significant in effect: it would change federal regulatory treatment that affects criminal penalties, research access, prescribing/registration pathways, enforcement priorities, and interactions with banking and other federal programs. No new funding or deadlines for other agencies are created beyond the 60-day ordering requirement.